Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSPTONIOLO, Ricardo AlexandreFERNANDES, Francy de Brito FerreiraSILVA, MichelleDIAS, Rodrigo da SilvaLAFER, Beny2017-12-122017-12-122017JOURNAL OF AFFECTIVE DISORDERS, v.224, Special Issue, p.69-75, 20170165-0327https://observatorio.fm.usp.br/handle/OPI/24342Background: Depressive episodes and cognitive impairment are major causes of morbidity and dysfunction in individuals suffering from bipolar disorder (BD). Novel treatment approaches that target clinical and cognitive aspects of bipolar depression are needed, and research on pathophysiology suggests that mitochondrial modulators such as the nutraceutical creatine monohydrate might have a therapeutic role for this condition. Methods: Eighteen (N=18) patients with bipolar depression according to DSM-IV criteria who were enrollled in a 6-week, randomized, double-blind, placebo-controlled trial of creatine monohydrate 6 g daily as adjunctive therapy were submitted to neuropsychological assessments (Wisconsin Card Sorting Test, Digit Span subtest of the Wechsler Adult Intelligence Scale-Third Edition, Stroop Color-Word Test, Rey-Osterrieth complex figure test, FAS Verbal Fluency Test) at baseline and week 6. Results: There was a statistically significant difference between the treatment groups of the change on the total scores after 6 weeks in the verbal fluency test, with improvement in the group receiving adjunctive treatment with creatine. We did not find significant differences between the groups of the changes on other neuropsychological tests. Limitations: Small sample and lack of a control group of healthy subjects. Conclusions: Our trial, which was the first to investigate the cognitive effects of creatine monohydrate on bipolar depression, indicates that supplementation with this nutraceutical for 6 weeks is associated with improvement in verbal fluency tests in patients with this condition.engrestrictedAccessBipolar disorderDepressionCognitionAdjunctive therapyCreatine monohydrateRandomized controlled trialmagnetic-resonance-spectroscopyhuman brain1st-degree relativesoral supplementationsymptomatic statuseuthymic patientsyoung-adultsdisordermetaanalysisperformancearticleCopyright ELSEVIER SCIENCE BV10.1016/j.jad.2016.11.029Clinical NeurologyPsychiatry1573-2517